Operator: Good day, ladies and gentlemen, and welcome to the fourth quarter 2012 Endo Health Solutions Earnings Conference Call. My name is, Dorcel, and I will be your operator for today. At this time all participants are in listen-only mode. Later, we will conduct a question-and-answer session.
I would like to turn over the conference over to your host for today, Mr. Blaine Davis, Senior Vice President of Corporate Affairs. Please proceed, sir.
Blaine Davis - VP, Corporate Affairs: Thanks, Dorcel. Good afternoon everybody and thank you for joining us. With me on this morning's call are Dave Holveck, President and CEO of Endo; Julie McHugh, Chief Operating Officer; Dr. Ivan Gergel, Chief Scientific Officer; and Alan Levin, Chief Financial Officer.
After our prepared remarks, we'll open the call to your questions. I would like to remind you that any forward-looking statements by management are covered under the Private Securities Litigation Reform Act of 1995 and subject to change, risks, and uncertainties described in today's press release and in our filings with the SEC.
In addition, during the course of this call, we may refer to non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States and that may be different from non-GAAP financial measures used by other companies.
Investors are encouraged to review Endo's current report on Form 8-K filed with the SEC for Endo's reasons for including those non-GAAP financial measures in its earnings announcement. The reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures is contained in our sales and earnings press release issued earlier this morning.
Now I'd like to turn the call over to Dave.
David P. Holveck - President and CEO: Thanks Blaine. I'm happy to have the opportunity to address all of you this afternoon. 2012 was a challenging year for Endo and we believe that our investors are aware of that and so we remain focused on improved execution in 2013. We preparing for leadership transition as well. Earlier this week we announced the appointment of Rajiv De Silva as the next President and CEO of Endo health solutions. I am excited to move on to my next chapter and I believe that Rajiv is as well. When he takes the lead in a few weeks I believe who will do so for an organization that I aligned to round the objectives of continuing to improve the efficiency and performance of Endo.
Now for the fourth quarter of 2012 we reported revenues of $801 million and adjusted earnings of $1.62 per share. These results reflect a number of variables affecting our business including solid growth in a Qualitest segment in steady sequential performance for Opana ER and Voltaren Gel after disruptions to the supply chain of these products earlier last year.
Our reported or GAAP financial results reflect current estimates in terms of the valuation of certain of the Company's assets including AMS as well as some of the other potential liabilities associated with the legal matters and other related contingencies. Alan will discuss in further detail the effect of those items in few minutes.